Systemic CRP (C-reactive protein) has been associated with impaired lung function. A causal relationship would increase the value of CRP as both a diagnostic and therapeutic tool. We assessed the association between lung function parameters, circulating CRP and CRP polymorphisms using Mendelian randomization in efforts to attribute causality to known associations. Spirometric parameters of FEV 1 (forced expiratory volume in 1 s) and FVC (forced vital capacity) were determined in 2173 men participating in the Caerphilly Prospective Study. Lung function measures on 1021 participants were available at follow-up (mean, 16.8 years later). Serum CRP levels were measured at baseline, and three CRP polymorphisms were analysed. Haplotype analysis was performed. Serum CRP levels at baseline were inversely associated with contemporaneous FEV 1 and FVC as well as at follow-up (P < 0.001) even after adjustment for conventional confounders. Serum CRP was associated with FEV 1 decline (P = 0.04). All three CRP polymorphisms (rs1800947, rs1130864 and rs1205) predicted serum CRP; however, there were no clear associations of the polymorphisms or haplotypes with lung function or with lung function decline. In conclusion, serum CRP was associated with lung function cross-sectionally; however, CRP polymorphisms were not associated with lung function or decline, suggesting that the CRP-lung function relationship is due to reverse causality, an unmeasured confounding factor or only has a modest causal effect.
INTRODUCTION
Circulating CRP (C-reactive protein), an acute phase protein, has been used widely in studies evaluating associations between low-grade systemic inflammation and chronic respiratory disease. Several studies have demonstrated the association of CRP with impaired lung function, expressed as FEV 1 (forced expiratory volume in 1 s) in healthy subjects [1, 2] and additionally with greater decline in lung function [1] , although there are conflicting results [2] . The association of CRP with lung function has been shown to be independent of confounders such as smoking. Systemic inflammation has also been implicated in COPD (chronic obstructive pulmonary disease), which is associated with a lower FEV 1 and higher serum CRP [3, 4] .
Low-grade systemic inflammation has also been implicated in cardiovascular morbidity and mortality, and hence, an inflammatory link has been postulated in the observed relationship between lower lung function and more cardiovascular events [5] [6] [7] . CRP is a central target for predictive and possibly therapeutic purposes in both COPD and cardiovascular disease. Indeed, some studies have suggested there may be benefits from pharmacological lowering of serum CRP levels in at-risk populations [8] . However, reverse causality or confounders may explain the associations [9, 10] .
In the present study, we hypothesized that a causal role for CRP in reducing lung function could be identified by the method of Mendelian randomization: the CRP gene contains SNPs (single nucleotide polymorphisms), which are known to determine baseline serum CRP levels. If higher serum CRP levels reduce lung function, then a CRP polymorphism that was associated with higher levels of serum CRP should also lead to impaired lung function [11] . By Mendelian laws of inheritance, alleles are inherited independently of each other and randomly at a population level and tend not to be associated with confounding factors [12] . Furthermore, disease processes do not influence germline genetic variants, so reverse causation, whereby disease processes influence apparent exposures, rather than vice versa, will also be avoided [12] . Our study would thereby mimic a randomized trial [13] . Sunyer et al. [14] employed this strategy in their small cross-sectional study of post-MI (myocardial infarction) survivors in Italy. Similarly, two studies demonstrate conflicting results for an association of CRP polymorphisms with the development or presence of COPD [15, 16] .
In the present study, we examine the association between three previously well-studied CRP polymorphisms (rs1130864, rs1800947 and rs1205) and haplotypes, circulating CRP levels and the continuous variables of lung function of FEV 1 and FVC (forced vital capacity), and with lung function decline. These results allow us to explore whether the existing association between serum CRP and lung function is explained by residual confounding, reverse causation or implicates a genuine role for inflammation on adverse lung function.
MATERIALS AND METHODS

Subjects
The Caerphilly Prospective Study is a population-based male cohort study of all men aged between 45 and 59 years who were resident in the small South Wales town of Caerphilly [17] . The initial examination (phase 1) took place between 1979 and 1983, where 2512 of the 2818 eligible men (89 %) were recruited. An additional 447 patients were recruited at phase 2. Men were re-invited for further follow-up approximately every 5 years. The last follow-up (phase 5) occurred between 2002 and 2004.
Subjects gave written informed consent, and the study had the approval of the local research ethics committee. At commencement, a detailed questionnaire was administered, and review of the subjects' personal and medical history was collected. Items included their occupational social class (grouped as nonmanual/manual), any established diagnoses of ischaemic heart disease, diabetes mellitus or hypertension and their smoking habits. Smoking status was categorized according to never smoked, ex-smokers, pipe and cigar smokers or current cigarette smokers (1-15 and 15+ cigarettes/day).
At phase 5, smoking status was re-established by classification into never, ex-and current smokers.
Clinic measures
Height in bare feet was measured using a Holtain stadiometer and weight in light clothes using standardized scales. From this, BMI (body mass index) was calculated (in kg/m 2 ) as a measure of obesity.
Spirometry
Spirometry at phase 2 was performed using the McDermott spirometer in a standing position. The FEV 1 , FVC and their ratio (FEV 1 /FVC) were calculated. An acceptable result was noted if the two valid, best traces of the three performed had less than 100 ml variability in FEV 1 . At phase 5, spirometry was performed using the Vitalograph spirometer with the same strict criteria and methodology. All measurements were taken prebronchodilator.
Venous blood samples
At phase 2, subjects attended an early morning clinic having fasted overnight, and a blood sample was taken with minimal venous stasis. CRP was measured in a citrated sample, which had been centrifuged within 1 h and stored at −70 • C until analysed using a highsensitivity nephelometric assay (Dade-Behring). Intraand interassay CVs (coefficients of variation) for CRP were 4.7 and 8.3 % respectively. The samples were analysed in 2000. Values are reproducible, stable over time and the methods highly standardized [18] .
Genotyping
Genetic variants of the CRP gene on chromosome 1q21-q23 were identified on blood samples taken at phase 4. Three SNPs were used in the analysis; rs1130864 (G→A base change in the 3 untranslated region, AF449713 position 3014), rs1800947 (C→G base change at codon 188, AF449713 position 2667) and rs1205 (C→T base change in the 3 flanking/untranslated region, AF449713 position 3872). These SNPs were chosen on the basis of available evidence showing their replicable and robust association with circulating CRP levels [19] [20] [21] . Genotyping was undertaken by Kbiosciences, which designed and used assays based on its proprietary competitive allele-specific PCR system method (www.kbioscience.co.uk). All assays were validated before use with a standard 96-well validation plate used by Kbiosciences. All variants were checked for adherence to Hardy-Weinberg equilibrium to avoid gross genotyping error, and a small number of internal validations and non-DNA test controls were used to validate genotyping after assay. HardyWeinberg equilibrium was tested at each SNP locus on a contingency table of observed compared with predicted genotypic frequencies using an exact test. Our allelic frequencies at rs1800947 represent the base on the antisense strand, and C and G frequencies are therefore reversed in our analyses.
Statistical analysis
Statistical analysis was conducted in Stata version 10. Circulating CRP was log 10 -transformed, as it was not normally distributed. We have expressed results as backtransformed geometric means for serum CRP levels. All analyses involving lung function were adjusted for age (at specific phase) and height. While examining the effects of adjusting for more curvilinear models with different age variables, we found that this did not improve the model significantly; hence the linear model for the age variable was used as the best simplest fit.
For the analyses, smoking status was grouped into never-(non)smokers, ex-smokers at phase 2, smokers at phase 2 and smokers at both phases 2 and 5. Subjects with a heterozygous state for rs1800947 (i.e. C:G) were grouped with the homozygous genotype (G:G) due to low numbers [six (phase 2) and four (phase 5) subjects had the G:G genotype]. All three polymorphisms were found to be in Hardy-Weinberg equilibrium.
We used linear regression models to assess the association between CRP polymorphisms, serum CRP level and lung function tests. We then introduced various confounders in the model to assess any change in the association between serum CRP levels and lung function tests (BMI, smoking status, presence of ischaemic heart disease, diabetes or hypertension).
Haplotypes were constructed using the genetic data analysis program SIMHAP (http://www.genepi.com.au). SIMHAP uses current estimation-maximization-based methods for the estimation of haplotypes from unphased genotype data [22] . The current implementation of SIMHAP uses the statistical computing package R (www.r-project.org) to resolve haplotypes and provide their posterior probabilities. After the construction of haplotypes, SIMHAP is also able to examine relationships between common CRP haplotypes and circulating CRP concentration. All possible haplotype configurations are resolved for each individual within the program itself, and the posterior probability of each configuration is calculated. Association analyses within the generalized linear model framework then uses simulation to correctly deal with the uncertainty around imputed haplotypes. In the case of plasma CRP concentration, mean values by common CRP haplotype were derived from the regression coefficients and CIs (confidence intervals) estimated by SIMHAP. For these analyses, all common haplotypes were run in the model assuming additive effect of each haplotype and setting a baseline haplotype as the most common in this sample (1000 iterations were used).
RESULTS
In phase 2, there were 2398 participants, of which 2173 individuals had valid lung function measures. By the time the men were rescreened for phase 5, only 1225 men were seen for whom we obtained valid lung function data on 1021 (83 %). For the men not seen, 667 had died, 86 had moved out of the area, 125 could not be traced and 295 refused to participate. Lung function at phase 5 was measured on an average of 16.8 years later (interquartile range 16 to 18 years). Basic participant characteristics as well as baseline data on non-participants are shown (Table 1) .
There were differences in the mean values or percentages of participants in phase 2 who have followup lung function measures at phase 5 compared with participants who have been lost to follow-up (Table 1) . These findings are largely consistent with the healthy survivor effect: participants who have been lost to followup (i.e. likely deceased) are more likely to have had worse lung function, been heavier smokers and suffered from concomitant cardiovascular disease or diabetes.
The relationship between alleles of the CRP polymorphism rs1800947 and serum CRP along with potential confounders are shown ( Table 2 ). The GMR (geometric mean ratio) for rs1800947 was 0.72 (95 % CI, 0.61, 0.84) (P < 0.001). We present results for this CRP polymorphism because it showed the strongest effects on serum CRP levels. The effects of rs1130864 and rs1205 polymorphisms on serum CRP were as follows: for rs1130864: GMR, 1.1 (95 % CI, 1.00, 1.21) (P = 0.04); for rs1205: GMR, 0.87 (95 % CI, 0.79, 0.95) (P = 0.002). No association was found between confounding variables and the polymorphisms except the rs1205 where the heterozygotes had a reduced risk of ischaemic heart disease of P = 0.01 compared with either the wild-type or mutant homozygous, which is likely to represent a chance finding. Phase 2 circulating CRP showed predictive value for both phases 2 and 5 lung function measures (P values all 0.02; Table 3 ). A one log-unit increase in phase 2 CRP level was associated with reduced FEV 1 and FVC (β = −0.13 and −0.14 respectively) and reduced FEV 1 /FVC ratio (β = −0.007) in phase 2.
Repeat analysis adjusting for potential confounders (BMI, smoking, presence of diabetes, ischaemic heart disease and hypertension, occupational status) had only minor effects on the β coefficients, with significant relationship maintained, except for FEV 1 /FVC ratio at phase 5 (P = 0.104); hence, the association with serum CRP could not be abolished by conventional confounders. The FEV 1 and FEV 1 /FVC decline, but not FVC, between phases 2 and 5 was associated with phase 2 serum CRP, but was attenuated in the fully adjusted model.
Having found associations between lung function with serum CRP, we then explored lung function in relation to the CRP genotype (Table 4 ). In phases 2 and 5, the CRP polymorphisms were not associated with lung function measures. Looking at lung function decline, however, there were weak associations with FVC decline. The rare rs1205 genotype (T:T) is associated with lower CRP levels, but was associated with an increased decline in FVC [β, 8.8 (95 % CI, 0.89, 16.79); P = 0.03]. The haplotype frequency was as published previously [23] . There were four common haplotypes with a frequency >5 %. Inclusion of the haplotype into the lung function model (either phase 2 or phase 5 or the longitudinal change) was not superior to excluding them (all P values for likelihood ratio test were all greater than a P value of 0.1). The lack of haplotype supporting data for the weak effect of polymorphism rs1205 on FVC decline reinforces the borderline P value and perhaps reflects multiple P values.
DISCUSSION
The present study demonstrates a robust association between CRP polymorphisms and serum CRP level, but in this large male cohort, no clear association between the CRP polymorphisms and lung function at either phase 2 or 5 or longitudinally was found, which was supported further by haplotype analysis [21, 24] . We have confirmed the inverse association between serum CRP and lung function parameters as previously described Genetic polymorphisms are useful tools in assessing causality and associations between established risk factors and chronic disease states [10, 27] . Their random acquisition by Mendelian inheritance laws equates to a randomized controlled trial, and relationships are not affected by confounders [13] . Van Durme et al.
[16] failed to demonstrate an association of CRP haplotype and polymorphisms with a risk of developing COPD, although, in that study, the definition of COPD appears to be either physician-based or according to spirometric evaluation alone, with 'probable COPD' potentially encompassing a wider range of diagnosis and not dependent necessarily on spirometry. In parallel, spirometric definitions of COPD according to the method protocol presented could have encompassed other non-COPD airways obstruction as smoking history, diurnal variation and atopic features did not appear to be a requisite. Our present study is consistent with that report, but we have extended into the natural history of lung function deterioration, the intermediary of developing disease such as COPD or another chronic respiratory disease.
In the small cross-sectional study on a limited number of post-MI patients recruited into the Italian AIRGENE study, Sunyer et al. [14] explored polymorphisms within the CRP and other inflammatory marker genes, observing that the rs1205 CRP polymorphism and one haplotype were associated with better lung function, the rare rs1205 polymorphism being associated with lower circulating CRP levels. However, by the nature of that study, the participants all had a cardiovascular history and were pre-selected by being the 'survivor' subset of MI. In our present study, the rate of decline was clearly only possible in those that had survived the follow-up period, but was strengthened by the cross-sectional data (at two time-points) and was not reliant on every subject surviving a major cardiovascular insult. Meanwhile, Yanbaeva et al. [15] detected an increased allele frequency between patients with COPD and controls for the CRP SNP rs1800947, although its significance after adjusting for age, sex and tobacco consumption was lost.
The haplotype inclusion was consistent with chance, and interestingly, the biggest difference in haplotype frequency was H2 (24.2 % in COPD patients and 30.3 % in the controls), yet H2 showed only a modest effect on CRP (P = 0.34). They did detect, however, a more clear association of a 4-fold increased COPD risk with IL-6 (interleukin-6) polymorphism, yet this was associated with a lower CRP level.
The inverse association of circulating CRP with lung function measures may thus indicate that reverse causality is the link, with impaired lung function causing the elevated circulating CRP. In patients with COPD, there is an apparent persisting inflammatory state with further elevation in inflammatory mediators at times of exacerbations [3, 28] . In addition, serum inflammatory status has been associated with lung function in apparently healthy subjects, even in never smokers [28] . However, in patients with mild-to-moderate COPD, there was no parallel in inflammatory mediators in the sputum and serum [29] . Similarly, in healthy subjects, there was no set systemic response in subjects when exposed to inhalational lipopolysaccharide [30] . Both of these studies suggest that the systemic inflammation is not simply overspill from the airways component.
The elevated serum CRP in patients with lower lung function may be mediated through other pathways, e.g. IL-6 is an upstream mediator of CRP production. Indeed, Yanbaeva et al. [15] found a much stronger relationship of IL-6 polymorphism with a diagnosis of COPD than with the CRP polymorphisms; however, this polymorphism was actually related to lower circulating CRP levels. He et al. [31] have recently reported SNPs to IL-6 associated with lung function decline and susceptibility to COPD in smokers; however, this requires replication. Alternatively, an as yet, unknown common mediator may be the key. In a similar manner, whereas serum CRP has been associated with atherosclerosis and with the metabolic syndrome, CRP genotypes have failed to be associated with arterial stiffness, carotid-intima thickness, the metabolic syndrome or coronary heart disease [10, 23, [32] [33] [34] Our present study has several strengths by being a large community-based study of unselected male population. It examined the associations both cross-sectionally and with longitudinal measures of lung function decline over a long period of time. The latter is a much more sensitive phenotypic measure, as cross-sectional measures cannot differentiate between developmental and degenerative trajectories over the life course [35] . For lung function decline, there was likely a healthy survivor effect, but the lack of association of genotype with lung function at either cross-sectional analysis strengthens the lack of association with decline. Our sample size cannot rule out moderate-sized effects given our confidence intervals. However, to avoid the problems of publication bias, it is important that such results are reported, which can then be included in a meta-analysis to explore small or modest effect sizes. Unfortunately, from the data collected, smoking pack years could not be calculated. It must be borne in mind that the Caerphilly Prospective study is limited to Welsh men only and, therefore, may not be generalizable to women. Although similar aetiology is likely, verification is required. Similarly, it is not generalizable to other geographical areas, as there are differences. Lung function measures were pre-bronchodilator and thus may include asthmatics. However, our aim a priori was not to diagnose disease states, but to explore the lung function as a continuous variable and over time. Mendelian randomization provides an opportunity to test causality. In general, limitations of this approach include confounding by polymorphisms in linkage disequilibrium with the polymorphism being studied, pleiotropy of the specific polymorphism, compensation during development of the effect of the polymorphism or whether there was not a suitable functional polymorphism [12] . However, for the present paper, we had recognized functional polymorphisms and we measured potential confounders in order to overcome these.
In conclusion, we have demonstrated that CRP is inversely associated with lung function parameters of FEV 1 and FVC. However, the CRP genotypes are not associated with lung function, and for the first time, we demonstrate they are not associated with lung function decline. This implies there may be no causal association, though we cannot rule our small effect estimates. We believe that the association between CRP and lung function is more likely to reflect reverse causation or an unknown common mediator. 
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